Form 4: Revolution Medicines CFO Sells Shares to Cover Tax Obligations

Chief Financial Officer of Revolution Medicines, Jack Anders, sold 1,864 shares of common stock on March 17, 2025, to cover tax obligations related to vesting restricted stock units.

Summary

• On March 17, 2025, Jack Anders, the Chief Financial Officer of Revolution Medicines, sold 1,864 shares of the company's common stock.
• The sale was executed at a price of $39.0403 per share.
• This transaction was made pursuant to a Rule 10b5-1 trading plan adopted on May 31, 2023.
• The purpose of the sale was to satisfy the reporting person's tax withholding obligations upon the vesting of restricted stock units (RSUs) after July 15, 2023.
• Following the transaction, Anders directly owns 115,006 shares of Revolution Medicines, Inc., which includes 60,150 RSUs.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the transaction is a routine sale of shares for tax purposes under a pre-arranged trading plan. It doesn't indicate any fundamental change in the company's prospects.

Industry Context

Sales of shares by company executives are a normal part of corporate governance, especially when related to tax obligations from vesting equity. The use of a 10b5-1 plan is a common practice to avoid insider trading accusations.

Stakeholder Impact

• The sale of shares by the CFO may have a minor impact on shareholders, but it is unlikely to be significant given the relatively small number of shares sold and the pre-planned nature of the transaction.

Key Dates

Keywords

Revolution Medicines, RVMD, Jack Anders, CFO, Form 4, Share Sale, Rule 10b5-1, Restricted Stock Units, Tax Obligations